BHB-1893 Versus Metoprolol for Symptomatic Obstructive Hypertrophic Cardiomyopathy

What this study involves

The registry says this study is recruiting. Individual locations may have different availability.

Study type

Interventional

Phase

Phase 3

Age range

18 years - 85 years

Sex eligible

All sexes

Healthy volunteers

Not accepted

Participants

210 Estimated

These are starting points, not an eligibility decision. The research team must review the full requirements.

About the research

The main purpose of this trial is to find out whether BHB-1893 works better than metoprolol in adults with symptoms of obstructive hypertrophic cardiomyopathy (oHCM). The trial includes adults who are currently being treated for oHCM or who have not yet been treated.

Who may be able to participate?

The list below is the sponsor’s full registry wording. It can include conditions, prior treatment, test results and other requirements. A match in search does not mean you qualify.

Key Inclusion Criteria:

• Diagnosed with oHCM per the protocol specified criteria
• NYHA Class II or III at screening visits
• KCCQ-CSS that meets the protocol specified criteria at screening visits
• Adequate acoustic windows for echocardiography

Key Exclusion Criteria:

• Medical indication for either β-blocker or calcium-channel blocker therapy, other than oHCM, prohibiting drug discontinuation
• History of intolerance or medical contraindication to β-blocker therapy
• Resting systolic blood pressure (SBP) of \>160 millimeters of mercury (mmHg) at screening visits
• Resting heart rate of \>100 beats per minute (bpm) at screening visits
• Significant valvular heart disease, defined as:

• Moderate to severe valvular aortic stenosis or fixed subaortic obstruction;
• Mitral regurgitation not due to systolic anterior motion of the mitral valve (per Investigator's judgment)

Other protocol-defined criteria apply.

Treatment, groups and participation

The registry may describe treatments and study duration without a complete visit calendar. Ask the study team for the exact schedule, procedures, risks, costs and alternatives. Keep your usual care plan unless your treating clinician tells you otherwise.

Assignment

Random assignment

Masking

Quadruple masked

What researchers are measuring

Outcome measures describe what is being studied. They are not proof that a treatment works.

Primary measures

Secondary measures

Research locations (4)

The overall study status and a local site’s status can differ. Confirm that location’s availability before traveling.

4 locations

Study team and timeline

Lead sponsor

Braveheart Bio, Inc.

Study start

Sep 2, 2026 Actual

Primary completion

2028-10 Estimated

Study completion

2028-11 Estimated

First posted

Aug 10, 2026 Actual

Last updated

Nov 10, 2026 Actual

Official study contacts